VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
TWST
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
TWSTTwist Bioscience Corporation
$91.03$5.7B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

TWST logoTwist Bioscience Corporation(TWST)Earnings, Financials & Key Ratios

TWST•NASDAQ
$91.03
Price updated Jul 7, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryLab Consumables and Sample Preparation
AboutTwist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.Show more
  • Revenue$377M+20.3%
  • EBITDA-$111M+41.2%
  • Net Income-$78M+62.8%
  • EPS (Diluted)-1.30+63.9%
  • Gross Margin50.72%+19.0%
  • EBITDA Margin-29.58%+51.1%
  • Operating Margin-36.18%+48.7%
  • Net Margin-20.63%+69.1%
  • ROE-16.43%+56.9%

TWST Price & Volume

Twist Bioscience Corporation (TWST) stock price & volume — 10-year historical chart

Loading chart...

Persistent Operating Losses Challenge Growth Scaling Trajectory

Investment Thesis • Updated 2026Q2

VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and dilution risk

Key Thesis Takeaways

  • Twist Bioscience continues to demonstrate top-line expansion, yet the company faces significant headwinds as revenue growth decelerated to 19.3% in 2026Q2 while operating expenses remain elevated.
  • The reliance on high R&D spending and substantial stock-based compensation of $18.9M in 2026Q2 obscures the path to sustainable profitability.
  • Investors should monitor the company's ability to achieve operational leverage, as the current cash burn and negative free cash flow margins of -23.1% threaten long-term liquidity without further capital intervention.

Verdict Logic

the company's persistent operating cash burn and the erosion of its cash buffer from $266.3M in 2024Q1 to $122.7M in 2026Q2 suggest significant execution risk regarding future self-sustainability.

TWST Growth Metrics

Twist Bioscience Corporation (TWST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years33.11%
3 Years22.76%
TTM17.77%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM57.48%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM59.2%

Return on Capital

10 Years-51.62%
5 Years-29.91%
3 Years-29.32%
Last Year-24.92%

TWST Recent Earnings

Twist Bioscience Corporation (TWST) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 4, 2026
Metric
Actual
Est
EPS
$0.62-26.5%
$0.49
Rev
$111M+2.9%
$108M
Q1 2026
Feb 2, 2026
Metric
Actual
Est
EPS
$0.50-4.2%
$0.48
Rev
$104M+1.8%
$102M
Q4 2025
Nov 14, 2025
Metric
Actual
Est
EPS
$0.45+10.0%
$0.50
Rev
$99M+1.7%
$97M
Q3 2025
Aug 4, 2025
Metric
Actual
Est
EPS
$0.47+13.0%
$0.54
Rev
$96M-1.4%
$97M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 4, 2026
$0.62vs $0.49-26.5%
$111Mvs $108M+2.9%
Q1 2026Feb 2, 2026
$0.50vs $0.48-4.2%
$104Mvs $102M+1.8%
Q4 2025Nov 14, 2025
$0.45vs $0.50+10.0%
$99Mvs $97M+1.7%
Q3 2025Aug 4, 2025
$0.47vs $0.54+13.0%
$96Mvs $97M-1.4%
Based on last 12 quarters of dataView full earnings history →

Latest TWST News

Recent stock market news and headlines for Twist Bioscience Corporation (TWST)

Forbes·Jun 17, 2026
Ozempic Linked To Lower Risk Of Violence In New Study

The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medications become more widespread.

Peers Comparison

Key metrics vs top competitors for Twist Bioscience Corporation (TWST)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
TWST logoTWSTTwist Bioscience CorporationCurrent
$91.03$5.67B-70.0220.32%-20.63%-16.43%—
ILMN logoILMNIllumina, Inc.
$191.76$29.13B35.19-0.78%19.43%32.84%—
PACB logoPACBPacific Biosciences of California, Inc.
$1.56$484.54M-0.863.89%-80.34%-488.45%—
BEAM logoBEAMBeam Therapeutics Inc.
$37.92$3.9B-46.81120.01%-49.17%-5.89%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$17.43$1.96B-4.5716.92%-597.04%-57.27%—
GH logoGHGuardant Health, Inc.
$162.92$21.6B-49.0732.88%-40.1%——

Compare TWST vs Peers

Twist Bioscience Corporation (TWST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ILMN

Most directly comparable listed peer for TWST.

Scale Benchmark

vs TMO

Larger-name benchmark to compare TWST against a more recognizable public peer.

Peer Set

Compare Top 5

vs ILMN, PACB, BEAM, NTLA

TWST SEC Filings & Documents

Twist Bioscience Corporation (TWST) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 4, 2026·SEC

Material company update

Feb 17, 2026·SEC

Material company update

Feb 6, 2026·SEC

10-K Annual Reports

1
FY 2025

Nov 17, 2025·SEC

10-Q Quarterly Reports

4
FY 2026

May 4, 2026·SEC

FY 2026

Feb 2, 2026·SEC

FY 2025

Aug 4, 2025·SEC

Get notified when TWST posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

TWST Frequently Asked Questions

Twist Bioscience Corporation (TWST) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Twist Bioscience Corporation's revenue?

Twist Bioscience Corporation (TWST) reported $409.5M in revenue for fiscal year 2025. This represents a 17947% increase from $2.3M in 2016.

How fast is Twist Bioscience Corporation growing?

Twist Bioscience Corporation (TWST) grew revenue by 20.3% over the past year. This is strong growth.

Is TWST profitable?

Twist Bioscience Corporation (TWST) reported a net loss of $81.3M for fiscal year 2025.

Dividend & Returns
What is TWST's return on equity?

Twist Bioscience Corporation (TWST) has a return on equity (ROE) of -16.4%. Negative ROE indicates the company is unprofitable.

What is Twist Bioscience Corporation's free cash flow?

Twist Bioscience Corporation (TWST) had negative free cash flow of $95.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in TWST back in 2016?

Total return calculator · dividends reinvested · 10+ years of data

See returns →